Akira Sezai

Dr. Akira Sezai

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in JACC
Verified
Journal Article
Closed access
ASAkira Sezai
Akira Sezai
MHMitsumasa Hata
Mitsumasa Hata
TNTetsuya Niino
Tetsuya Niino
IYIsamu Yoshitake
Isamu Yoshitake
SUSatoshi Unosawa
Satoshi Unosawa
AHAtsushi Hirayama
Atsushi Hirayama

1 January 2013 in Circulation Journal
Verified
Journal Article
Open access
PDF file
ASAkira Sezai
Akira Sezai
MSMasayoshi Soma
Masayoshi Soma
KNKin-Ichi Nakata
Kin-Ichi Nakata
MHMitsumasa Hata
Mitsumasa Hata
IYIsamu Yoshitake
Isamu Yoshitake
MSMotomi Shiono
Motomi Shiono
Background: Febuxostat has been reported to have a stronger effect on hyperuricemia than allopurinol. Methods and Results: Cardiac surgery patients with hyperuricemia (n=141) were randomized to a febuxostat group or an allopurinol group. The study was single-blind, so the treatment was not known by the investigators. The primary endpoint was serum uric acid (UA) level. Secondary endpoints included serum creatinine, urinary albumin, cystatin-C, oxidized low-density lipoprotein (LDL), eicosapentaenoic acid/arachidonic acid ratio, total cholesterol, triglycerides, LDL, high-density lipoprotein, high-sensitivity C-reactive protein, blood pressure, heart rate, pulse wave velocity (PWV), ejection fraction, left ventricular mass index (LVMI), and adverse reactions. UA level was significantly lower in the febuxostat group than the allopurinol group from 1 month of treatment onward. Serum creatinine, urinary albumin, cystatin-C and oxidized LDL were also significantly lower in the febuxostat group. There were no significant changes in systolic blood pressure, PWV, and LVMI in the allopurinol group, but these parameters all had a significant decrease in the febuxostat group. Conclusions: Febuxostat was effective for high-risk cardiac surgery patients with hyperuricemia because it reduced UA more markedly than allopurinol. Febuxostat also had a renoprotective effect, inhibited oxidative stress, showed anti-atherogenic activity, reduced blood pressure, and decreased PWV and LVMI. (Circ J 2013; 77: 2043–2049)

1 September 2009 in JACC
Verified
Journal Article
Closed access
ASAkira Sezai
Akira Sezai
MHMitsumasa Hata
Mitsumasa Hata
TNTetsuya Niino
Tetsuya Niino
IYIsamu Yoshitake
Isamu Yoshitake
SUSatoshi Unosawa
Satoshi Unosawa
KMKazutomo Minami
Kazutomo Minami

1 October 2015 in Journal of Cardiology
Verified
Journal Article
Closed access
ASAkira Sezai
Akira Sezai
MSMasayoshi Soma
Masayoshi Soma
KNKin-Ichi Nakata
Kin-Ichi Nakata
SOShunji Osaka
Shunji Osaka
YIYusuke Ishii
Yusuke Ishii
MSMotomi Shiono
Motomi Shiono

5 June 2019 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
ASAkira Sezai
Akira Sezai
HSHisakuni Sekino
Hisakuni Sekino
SUSatoshi Unosawa
Satoshi Unosawa
MTMakoto Taoka
Makoto Taoka
SOShunji Osaka
Shunji Osaka
MTMasashi Tanaka
Masashi Tanaka
Background: Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field. We conducted a study of canagliflozin in patients with chronic heart failure and type II diabetes. Methods: Thirty-five Japanese patients with chronic heart failure and type II diabetes were treated with canagliflozin for 12 months. The primary endpoints were the changes of subcutaneous, visceral, and total fat areas at 12 months determined by computed tomography. Secondary endpoints included markers of glycemic control, renal function, and oxidative stress, as well as lipid parameters, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), flow-mediated dilation (FMD), and echocardiographic left ventricular function. Results: All fat areas (subcutaneous, visceral, and total) showed a significant decrease at 12 months. ANP and BNP also decreased significantly, along with improvement of renal function, oxidized LDL, and E/e′, FMD increased significantly after canagliflozin treatment. Conclusion: Canagliflozin demonstrated cardiac and renal protective effects as well as improving oxidative stress, diastolic function, and endothelial function. This drug was effective in patients who had heart failure with preserved ejection fraction and could become first-line therapy for such patients with diabetes. Trial registration UMIN (http://www.umin.ac.jp/), Study ID: UMIN000021239

1 November 2012 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
ASAkira Sezai
Akira Sezai
TNTishiko Nakai
Tishiko Nakai
MHMitsumasa Hata
Mitsumasa Hata
IYIsamu Yoshitake
Isamu Yoshitake
MSMotomi Shiono
Motomi Shiono
AHAtsushi Hirayama
Atsushi Hirayama